The Liver Meeting 2022-American Association for the Study of Liver Diseases (AASLD) 73rd Annual Meeting

The Liver Meeting-the American Association for the Study of Liver Diseases (AASLD) 2022 annual meeting-returned to in-person attendance for the first time in 2 years since the COVID-19 public health emergency began and included a virtual option. Comprised of scientists and healthcare profession-als, AASLD is the leading organization committed to preventing and curing liver disease. The hottest meeting in hepatology, according to the AASLD, included plenary sessions, presenta-tions and over 4,800 scientific abstracts highlighting the latest scientific advancements in the field of hepatology. Research and clinical trial updates were provided in many specific liver disease areas, including hepatitis, fibrosis, nonalcoholic fatty liver disease, cirrhosis, nonalcoholic steatohepatitis, trans-plantation, and so on. Along with groundbreaking research in hepatology, many presentations included the impact of COVID-19 on patients with these diseases. This report highlights a selec-tion of presentations about treatment updates provided during the conference.

Automated summary

The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), took place in person for the first time in two years, with a virtual option available. AASLD, consisting of scientists and healthcare professionals, is the leading organization dedicated to liver disease prevention and cure. The meeting showcased the latest scientific advancements in hepatology through plenary sessions, presentations, and over 4,800 scientific abstracts. Updates on research and clinical trials in various liver disease areas, as well as the impact of COVID-19 on these patients, were emphasized.